放射性碘治疗甲状腺癌后鼻泪管阻塞手术风险预测:一项全国性队列研究
该研究基于韩国全国健康保险索赔数据库,纳入2007至2019年20至80岁甲状腺癌患者,按是否接受放射性碘治疗分为两组,评估鼻泪管阻塞手术风险。放射性碘组手术风险显著高于非放射性碘组(HR 7.50,95%CI 5.86-9.60,P<0.001),高剂量组和50岁以下患者风险更高。
要点
- 放射性碘组鼻泪管阻塞手术风险显著高于非放射性碘组,HR 7.50(95%CI 5.86-9.60,P<0.001)。
- 高剂量组风险显著增加,HR 14.15(95%CI 10.88-18.39);50岁以下患者风险显著增加,HR 15.54(95%CI 9.76-24.72)。
- 放射性碘组鼻泪管阻塞手术发生率为104.04/10万人年,平均发生时间为首次放射性碘暴露后3.8±2.1年。
核心结论
- 通过9年长期随访量化了放射性碘所致鼻泪管阻塞手术风险,可能有助于估计甲状腺癌患者放射性碘治疗相关的总体医疗负担。
- 作者认为应高度关注50岁以下患者的风险,尤其是接受高剂量治疗者。
研究设计与样本
- 全国性、基于人群的队列研究,使用韩国国家健康保险索赔数据库。
- 纳入2007至2019年韩国全国20至80岁全部甲状腺癌患者,按招募期间是否接受放射性碘治疗分为放射性碘组和非放射性碘组。
- 采用对数秩检验比较两组鼻泪管阻塞手术风险,Cox比例风险回归计算校正风险比(HR),并按年龄组、性别、放射性碘治疗次数和131I累积剂量分层分析。
主要发现
- 接受放射性碘治疗的55,371例甲状腺癌患者中,515例(0.93%)接受了鼻泪管阻塞手术;未接受放射性碘治疗的56,950例患者中,72例(0.13%)接受了该手术。
- 首次放射性碘暴露后鼻泪管阻塞手术的平均发生时间为3.8±2.1年。
- 放射性碘组鼻泪管阻塞手术发生率为104.04/10万人年。
- 放射性碘组鼻泪管阻塞手术风险显著高于非放射性碘组,HR 7.50(95%CI 5.86-9.60,P<0.001)。
- 高剂量组风险显著增加,HR 14.15(95%CI 10.88-18.39);50岁以下患者风险显著增加,HR 15.54(95%CI 9.76-24.72)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: To estimate the incident risk of surgical intervention for nasolacrimal duct obstruction after radioactive iodine (RAI) treatment and elucidate the high-risk group of patients with thyroid cancer (TC). Methods: This is a nationwide, population-based cohort study using data from the Korean National Health Claims database. Among the entire South Korean population aged between 20 and 80 years from 2007 to 2019, all patients with TC were included. Among all TC patients, a cohort was established by classifying it into the RAI and non-RAI groups according to whether RAI treatment was performed during the recruitment period. A log-rank analysis was used to evaluate the risk of nasolacrimal duct obstruction surgery in the RAI group compared with that in the non-RAI group. The Cox proportional hazards regression analysis was performed to calculate the adjusted hazard ratio (HR). The analysis was performed stratified by the age group, sex, frequency of RAI treatment, and cumulative dose of 131I. Results: Among 55,371 TC patients, who received RAI treatment, 515 (0.93%) underwent nasolacrimal duct obstruction surgeries, and among 56,950 TC patients, who did not receive RAI treatment, 72 (0.13%) underwent the surgeries. The average timing of incident nasolacrimal duct obstruction surgery was 3.8 ± 2.1 years after the first exposure to RAI. The incidence rate of nasolacrimal duct obstruction surgery was 104.04/100,000 person-years in the RAI group. There was a significantly higher risk of nasolacrimal duct obstruction surgery (HR 7.50 [confidence interval, CI: 5.86-9.60], p < 0.001) in the RAI group than in the non-RAI group. The risks significantly increased in the high-dose group (HR 14.15 [CI: 10.88-18.39]) and those younger than 50 years (HR 15.54 [CI: 9.76-24.72]). Conclusion: We quantified the risk of RAI-induced nasolacrimal duct obstruction surgery through a long-term follow-up of 9 years, which may contribute to estimating the general health care burden related to RAI treatment for TC patients in a practical setting. Great attention should be paid to its risk in patients younger than 50 years, especially in those treated with high doses.
引用
- Lee JY, Woo KI. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study. Thyroid. 2022. PMID: 34894720. doi:10.1089/thy.2021.0418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。